Intravitreal Injections of Ranibizumab With Deferred Laser Grid Laser Photocoagulation for Treatment of Diabetic Macular Edema With Visual Impairment

Poitiers University Hospital35 enrolled

Overview

In the prospective monocentric open label trial patients with diabetic macular edema will be treated with intravitreal injections of ranibizumab given for 3 months then with laser grid at month 4. During follow-up a ranibizumab injection will be performed every 2 months in case of best-corrected visual acuity decreased more than 5 letters.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetic Macular Edema

Interventions

ranibizumabDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 79 Years

Medical Language ↔ Plain English

Inclusion Criteria: * diabetes mellitus (1 or2) * decreased vision from Diabetic Macular Edema (study eye Best Corrected Visual Acuity\<69 letters using E.T.D.R.S testing) * macular edema Exclusion Criteria: * history of severe cardiac disease * stroke within 12 months * intraocular inflammation

Locations (1)

Chu de Poitiers

Poitiers, France

Outcomes

Primary Outcomes

Number of intravitreal injections of ranibizumab

Time frame: 1 years

Secondary Outcomes

best-corrected visual acuity

Time frame: 1 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.